At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
doxycycline monohydrate +1 moredrug
Likely dose
doxycycline monohydrate 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Effect of Doxycycline Verses Placebo on Diabetic Retinopathy Progression and Retinal Function in Patients With Severe Non-proliferative or Mild or Moderate (Non-high-risk) Proliferative Diabetic Retinopathy
In Brief
A Phase 2 clinical trial evaluating doxycycline monohydrate and placebo for Diabetic Retinopathy. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This 24 month randomized research study will evaluate whether doxycycline can 1) slow the deterioration or improve retinal function and/or 2) induce regression, or slow progression, of diabetic retinopathy in participants over 18 years of age with type 1 or type 2 diabetes with severe non-proliferative or early proliferative diabetic retinopathy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Retinopathy
CountriesUnited States
CollaboratorsJuvenile Diabetes Research Foundation
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2007
Enrollment StartJul 2008
Primary CompletionMay 2012
TodayJul 2026
First PostedAug 6, 2007
Enrollment StartJul 1, 2008
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 18.9 years ago
Interventions
doxycycline monohydratedrug
50mg once daily for 24 months
placebodrug
placebo taken once daily for 24 months